Document and Entity Information
Document and Entity Information | Jun. 30, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Document Period End Date | Jun. 30, 2021 |
Entity Registrant Name | Arcadia Biosciences, Inc. |
Entity Central Index Key | 0001469443 |
Entity Emerging Growth Company | false |
Entity File Number | 001-37383 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 81-0571538 |
Entity Address, Address Line One | 202 Cousteau Place |
Entity Address, Address Line Two | Suite 105 |
Entity Address, City or Town | Davis |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 95618 |
City Area Code | 530 |
Local Phone Number | 756-7077 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common |
Trading Symbol | RKDA |
Security Exchange Name | NASDAQ |
Amendment Description | On July 2, 2021, Arcadia Biosciences, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) with the Securities and Exchange Commission to report the voting results of the 2021 annual meeting of stockholders (the “Annual Meeting”), including, among other matters, the approval, on an advisory basis, of the frequency of future non-binding stockholder advisory votes to approve the compensation of the Company’s named executive officers (“say-on-pay votes”). The sole purpose of this Current Report on Form 8-K/A is to disclose, pursuant to Item 5.07(d) of Form 8-K, the Board of Directors’ determination on the frequency of future say-on-pay votes. Except for the foregoing, this Current Report on Form 8-K/A does not modify or update any other disclosure contained in the Original Report, and this Current Report on Form 8-K/A should be read in conjunction with the Original Report. |